anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Optimal pain management in patients with advanced cancer often requires multiple pharmacological interventions and multimodal approach. Ketamine is an anaesthetic agent with increasing evidence supporting its use for pain. Due to its N-methyl-D-aspartate antagonism and its activity at opioid receptors, it is an adjuvant to traditional analgesics. Ketamine has a safety profile with limited experience of oral prolonged use in patients with cancer. We report a case of a 40-year-old man with refractory neuropathic cancer-related pain. Opioid rotation to methadone was previously performed, coanalgesics were added, the patient was reluctant to invasive anaesthetic techniques and his pain was poorly controlled. Ketamine was added to attenuate pain keeping functionality. This is a report of a patient with refractory cancer pain treated with methadone and ketamine orally during months, without reported side effects. Ketamine's use to treat pain is increasing along with its evidence of efficacy for long-term oral use.
The potential prognostic influence of genetic aberrations on chronic lymphocytic leukaemia (CLL) can vary based on various factors, such as the immunoglobulin heavy variable (IGHV) status. We conducted an integrative analysis on genetic abnormalities identified through cytogenetics and targeted next-generation sequencing in 536 CLL patients receiving first-line chemo(immuno)therapies (CIT) as part of two prospective trials. We evaluated the prognostic implications of the main abnormalities, with specific attention to their relative impact according to IGHV status. In the entire cohort, unmutated (UM)-IGHV, complex karyotype, del(11q) and ATM mutations correlated significantly with shorter progression-free survival (PFS). Focusing on the subset of mutated IGHV (M-IGHV) patients, univariate analysis showed that complex karyotype, del(11q), SF3B1 and SAMHD1 mutations were associated with significant lower PFS. The prognostic influence varied based on the patient's IGHV status, as these abnormalities did not affect outcomes in the UM-IGHV subgroup. TP53 mutations had no significant impact on outcomes in the M-IGHV subgroup. Our findings highlight the diverse prognostic influence of genetic aberrations depending on the IGHV status in symptomatic CLL patients receiving first-line CIT. The prognosis of gene mutations and cytogenetic abnormalities needs to be investigated with a compartmentalized methodology, taking into account the IGVH status of patients receiving first-line BTK and/or BCL2 inhibitors.
Resilient controls will self-administer 24 IUs of OT nasal spray at 10:30 a.m.on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes.Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt sunitinib malate and dose reduce for 24-hour urine protein of 3 or more grams. Discontinue sunitinib malate capsules for patients with nephrotic syndrome or repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions. The safety of continued sunitinib malate treatment in patients with moderate to severe proteinuria has not been evaluated.
The invention provides a novel vaccine with the same immunoefficiency as the prior infectious laryngotracheitis virus (ILTV) attenuated vaccine and capable of overcoming dormant infection induced by the attenuated vaccine. The invention provides the nucleotide sequence and amino acid sequence of an ILTV glycoprotein D (gD) and a preparation method, as well as a recombinant vaccine containing a viral vector (fowlpox virus vector) and ILTV gD. The fowlpox virus is obtained by homologous arm recombination of ILTV gD. The invention also provides the preparation method of the recombinant vaccine. The invention clones gD gene of ILTV Henan isolate, and performs animal experiments of the immunoprotection of the recombinant fowlpox virus. The novel vaccine has the same immunoefficiency as the prior ILTV attenuated vaccine and is capable of overcoming the shortcomings of the attenuated vaccine. The invention is convenient for large-scale production, and provides a foundation for prevention and elimination of infectious laryngotracheitis (ILT).
Clinical and subclinical thyroid disease is usually used to describe patients with mild symptoms correlated to hyperthyroid or hypothyroid state. Thyroid ultrasonography could differentiate benign or malignant nodular lesion, together with fine needle aspiration cytology and surgical pathology. Thyrotropin (TSH, thyroid stimulating hormone) is the pivotal investigation in laboratory diagnosis to define subclinical thyroid diseases. An elevated TSH with normal free thyroxine and triiodothyronine levels in serum is defined to be subclinical hypothyroidism, and a subnormal TSH with normal thyroid hormone concentrations to be subclinical hyperthyroidism. Generally, the prevalence of subclinical hypothyroidism and hyperthyroidism were reported as 4% -10% \& 1%-2% in general population, respectively. Although subclinical thyroid disease is prevalent, there is still no consensus for screening clinical and subclinical thyroid disease, including hyperthyroidism, hypothyroidism, nodular goiter and thyroid cancer. Under consideration of age, gender or familial history of autoimmune thyroid disease. However, screening for thyroid dysfunction should be considered in some high risk patients, including 1) elderly; 2) history of atrial fibrillation; 3) previous thyroid disease history; 4) other confirmed autoimmune diseases; 5) neck exposure of radiation (for example, nasopharyngeal cancer, post-radiation); 6) family history of probable autoimmune thyroid disease, and 7) pregnant state with prior thyroid disease history. Therapeutic decision for clinical and subclinical thyroid dysfunction should be considered individually. Therapeutic options will be anti-thyroid medications and/or radioactive iodine, and thyroidectomy could be considered with larger goiters for hyperthyroidism. For clinical and subclinical hypothyroidism, the therapeutic consideration should be aimed on reduction of progression to overt hypothyroidism, improving heart function, correction of dyslipidemia, and relieving senescence depressive mood. Thyroid ultrasonography will help us to keep long term observation of thyroid structural change. But long term outcome for treatment of such functional and structural thyroid diseases had not been recorded delicately in Taiwan. Further investigations should be observed in the future. The investigators hope to check the relationship between various thyroid diseases and biochemical survey/ultrasonography. The purpose of this study is aiming for early prevention and detection the potential risk factors for thyroid diseases in Taiwan.
The participants in this group will receive sedative music followed by stimulative music for up to 25 minutes each. Session two will occur two days after session one.
Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30-60 minutes on day 1 beginning with course 3. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
PURPOSE: A skin whitening composition is provided to produce a cosmetic product and soap for whitening. CONSTITUTION: A skin whitening composition contains Stichopus japonicus extract obtained by isolating Stichopus japonicus using methanol and distilled water or fraction thereof as an active ingredient. The fraction is isolated using water, distilled water, ethanol, or mixture solvent thereof. The fraction is an ethylacetate fraction of solid extract of Stichopus japonicus. The composition is a cosmetic composition or pharmaceutical composition. The pharmaceutical composition has pharmacological effects of preventing or treating melasma, fleck, or skin aging.
Preventing or treating neurodegenerative or dementia diseases characterized by molecular pathology of microtubuli-associated tau protein comprises administering a K252a derivative (I). Preventing or treating neurodegenerative or dementia diseases characterized by molecular pathology of microtubuli-associated tau protein comprises administering a K252a derivative (I) of formula 1 or its salt. R1COOR or CONHR; R : H, Me, Et or cyclopropyl; R2, R3H, F, Me, OH, NH2, NHMe or NMe2; and Z : (H,H) or O. Independent claims are also included for: (1) identifying inhibitors of neurofibrillar degeneration and their activity by incubating metabolically active mammalian brain section tissue with candidate compounds at various concentrations, provoking tau hyperphosphorylation with a PP2A (not defined) inhibitor, quantifying tau phosphoepitopes in the tissue or tissue extracts by immunoassay, and comparing the phosphoepitope provocation with that of untreated control tissue; (2) determining a suitable dose of an inhibitor of paired helical filament-like tau hyperphosphorylation for treating a disease characterized by neurofibrillar pathology by titrating the inhibitor in brain sections stimulated with a PP2A inhibitor to determine effective tissue concentrations and pharmacokinetically evaluating a dosage scheme to produce effective concentrations in the CNS of a subject; and (3) determining a suitable dose of an inhibitor of paired helical filament-like tau hyperphosphorylation for treating a disease characterized by neurofibrillar pathology by determining a normal level of a paired helical filament-like tau phosphoepitope in the cerebrospinal fluid of healthy control subjects of the same age group, increasing the dose of an inhibitor in a subject suffering from a form of neurofibrillar degeneration at intervals of several weeks or administering increasing doses of an inhibitor identified as above to individual subjects, immunochemically evaluating the reduction in paired helical filament-like tau phosphoepitope in the cerebrospinal fluid of the same subject immediately before the start of treatment and again after several weeks of continuous administration of the inhibitor, and comparing the level of paired helical filament-like tau phosphoepitope in cerebrospinal fluid before and after the start of treatment of a subject suffering from a form of neurofibrillar degeneration, and determining the effective dose as one that reduces the paired helical filament-like tau phosphoepitope level to the range occurring in healthy controls of the same age group. [Image] ACTIVITY : Neuroprotective; Nootropic; Antiparkinsonian; Cerebroprotective. MECHANISM OF ACTION : Tau hyperphosphorylation inhibitor. 9(S),12(R)-Epoxy-2,3,9,10,11,12-hexahydro-10(R)-amino-9-methyl-1-oxo-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxamide had an IC50 of 200 nM for inhibiting phosphorylation of AP422, AT8, AT100 and Thr231 epitopes in rat hippocampus sections, and 400 nM for inhibiting phosphorylation of the Ser262 epitope.
The Suboptimal health status questionnaire (SHSQ-25) is used to evaluate the suboptimal health status. The SHSQ-25 includes 25 questions. The score of the SHSQ-25 is from 0 to 100. Suboptimal health status is defined as the SHSQ-25 score above than 35. The higher scores of the SHSQ-25 one gets, the more severity of suboptimal health status he/she has. All participants are asked to fill in the SHSQ-25 before and after the intervention. If the score decreases after the intervention, it means that the suboptimal health status has been improved.

A monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology. Intervention technologies include a health information push technology and a field-effect meridian therapy instrument.
PURPOSE:The titled pharmaceutical preparation having extremely improved dissolution properties, useful for remedying angina pectoris or hypertension, obtained by blending nifedipine with a specific compound and casein, crushing them in a mixed state. CONSTITUTION:The titled pharmaceutical preparation containing ultrafine composition obtained by blending one or more selected from a group consisting of magnesium silicate, magnesium carbonate, dried aluminum hydroxide gel, magnesium oxide, magnesium metasilicate aluminate, synthetic hydrotalcite and magnesium alumina hydroxide with nifedipine and casein, crushing them in a mixed state together. Nifedipine is slightly soluble in water, an ultrafine composition obtained from crushing a two-component system of nifedipine and casein can not improve dissolution properties of nifedipine, however, addition of the compound to the system can improve dissolution effect. A blending ratio changes depending upon the component used, and, in case of magnesium silicate, 0.2-9pts.wt. magnesium silicate is used based on 1pt.wt. nifedipine.
(also see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS: Drug Interactions) 

CYP3A and CYP2C19 appear to be the predominant enzymes that metabolize nelfinavir in humans. The potential ability of nelfinavir to inhibit the major human cytochrome P450 enzymes (CYP3A, CYP2C19, CYP2D6, CYP2C9, CYP1A2 and CYP2E1) has been investigated in vitro. Only CYP3A was inhibited at concentrations in the therapeutic range. Specific drug interaction studies were performed with nelfinavir and a number of drugs. Table 6 summarizes the effects of nelfinavir on the geometric mean AUC, Cmax and Cmin of coadministered drugs. Table 7 shows the effects of coadministered drugs on the geometric mean AUC, Cmax and Cmin of nelfinavir.

For information regarding clinical recommendations see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS: Drug Interactions.
OBJECTIVES: This study aimed to identify the risk factors for postoperative atrial fibrillation in patients with valvular atrial fibrillation, and establish predictive models of atrial fibrillation recurrence.
METHODS: Overall, 224 patients who underwent radiofrequency ablation of atrial fibrillation from November 2014 to November 2020 were included. The statistical package for social sciences, X-tile, and R-studio were used for statistical analysis.
RESULTS: Patients were divided into training and validation sets according to a ratio of 3:1. The training set was analysed using univariate and multivariate Cox regression analysis and showed that preoperative uric acid > 401 μmol/L (P = 0.006), B-type natriuretic peptide > 202 ng/L (P = 0.042), hypersensitivity C-reactive protein > 6.1 mg/L (P = 0.026), erythrocyte sedimentation rate > 7.0 mm/h (P = 0.016), preoperative left atrial diameter > 48 mm (P = 0.031) were significantly correlated with the recurrence of atrial fibrillation after radiofrequency ablation in patients with valvular atrial fibrillation. In the training set, a Cox regression model of the five related factors was established using the R language. The C-index of the model was 0.82, and the area under the receiver operating characteristic curve was 0.831 (P < 0.001). Internal and external verification was performed in the training and validation sets, respectively, and both showed that the fit of the verification curve was relatively good at 3 months, 6 months, 1 year, and 3 years postoperatively. After calculating the weight of each related factor using the nomogram, a new risk predictive model (BLUCE) for postoperative atrial fibrillation was established.
CONCLUSIONS: In patients with atrial fibrillation, preoperative uric acid, B-type natriuretic peptide, hypersensitivity C-reactive protein, erythrocyte sedimentation rate, and left atrial diameter are risk factors for atrial fibrillation or atrial flutter recurrence after radiofrequency ablation. The BLUCE predictive model can distinguish high-risk groups of postoperative atrial fibrillation. High-risk patients in the BLUCE model were more likely to experience recurrence of atrial fibrillation after radiofrequency ablation and a low possibility of maintaining sinus rhythm.
BACKGROUND: Mechanical thrombectomy is an effective treatment method for large-vessel occlusion stroke (LVOS); however, it has limited efficacy for intracranial atherosclerotic disease (ICAD)-related LVOS. We investigated the use of cerebral blood volume (CBV) maps for identifying ICAD as the underlying cause of LVOS before the initiation of endovascular treatment (EVT).
METHODS AND RESULTS: We reviewed clinical and imaging data from patients who presented with LVOS and underwent endovascular treatment between January 2011 and May 2021. The CBV patterns were analyzed to identify an increase in CBV within the hypoperfused area and estimate infarct patterns within the area of decreased CBV. Comparisons were made between the patients with an increase in CBV and those without, and among the estimated infarct patterns: territorial, cortical wedge, basal ganglia-only, subcortical, and normal CBV. Overall, 243 patients were included. CBV increase in the hypoperfused area was observed in 23.5% of patients. A significantly higher proportion of ICAD was observed in those with increased CBV than in those without (56.4% versus 19.8%; P<0.001). Regarding the estimated infarct patterns on the CBV, ICAD was most frequently observed in the normal CBV group (territorial, 14.9%; cortical wedge, 10.0%; basal ganglia-only, 43.8%; subcortical, 35.7%; normal, 61.7%). CBV parameters, including "an increase in CBV," "normal CBV infarct pattern," and "an increase in CBV or normal CBV infarct pattern composite," were independently associated with ICAD.
CONCLUSIONS: An increased CBV or normal CBV pattern may be associated with ICAD LVOS on the pretreatment perfusion imaging.
<P>PROBLEM TO BE SOLVED: To provide new polypeptides and nucleic acid molecules encoding the polypeptides.  <P>SOLUTION: A secreted protein PRO 866 isolated from a human tissue type or other supply source, and the nucleic acids encoding the same. In addition, vectors and host cells which contain the nucleic acid sequences, respectively. Chimera polypeptide molecules which contain the polypeptides fused with heterologous polypeptide sequences. And a method for producing the polypeptides, and uses.  <P>COPYRIGHT: (C)2004,JPO
PROBLEM TO BE SOLVED: To obtain a hair restoring agent which contains a polyhydroxyfatty acid containing in Crataegus cuneata and the like as an active ingredient and possesses excellent hair restoring effect and high stability. SOLUTION: This hair restoring agent contains a polyhydroxyfatty acid (preferably 9,10-dihydroxyoctadecanoic acid), a polyhydroxyfatty acid ester and one or two compounds selected from these physiologically permissible salts as active ingredients. As the polyhydroxyfatty acid, for example, a commercially available one, a synthesized one and an extracted one from a natural product such as Crataegus cuneata and the like are usable. The hair restoring agent is usable as a component in cosmetics and medical compositions. In this case, the hair restoring agent is preferably contained in a content of 0.01-10wt.% based on the whole composition.  By this process, it is expected that the hair restoring agent which shows various effects, for example, promotion for extension of hair, preservation and resuscitation for hair, promotion for hair growing and suppression against loss of hair, is obtained.
Proteins that are released by hookworm larvae following infection, and which are highly immunogenic in experimental animals, are disclosed. Data indicates that these polypeptides are useful in a vaccine for hookworm as well as other soil-transmitted human and veterinary nematodiases. The proteins are also useful as a target for specific treatment of hookworm, and can be used in a diagnostic assay for hookworm, using standard protein detection techniques, especially those based on antibodies. DNA encoding the proteins has been isolated. The proteins can be made by recombinant means in a variety of hosts. The recombinant proteins, or fragments thereof, can be formulated as a vaccine. The recombinant proteins can also be used in an assay to detect antibodies to the protein produced in a previous hookworm infection. The recombinant proteins can also be used to produce antibodies which recognize the proteins. DNA encoding all or immunogenic parts of the proteins can be used as probes to detect the presence of hookworm nucleic acid. Such probes are useful in assays of tissue samples, body fluid samples, and hookworm infection sources. Antibodies to the proteins can be produced using standard immunological techniques. Such antibodies are useful in diagnostic assays to detect proteins produced during hookworm infection.
Arteriovenous malformations (AVM's) are the commonest vascular abnormalities of the gut. AVM's or Angiodysplasia may be acquired or inherited as in a hereditary hemorrhagic telangiectasia (HHT). Repeated episodes of gastrointestinal bleeding (GIB), especially in the elderly have been attributed to angiodysplasia. Clinically significant GIB may be also seen in up to 40% of HHT patients, usually in the fourth and fifth decades of life. GIB may manifest both as acute major hemorrhage, slow intermittent blood loss or a combination of these findings and patients may be symptomless, present with acute bleeding or iron deficiency anemia. Recurrent hemorrhage and persistent iron-deficiency anemia is common despite supplemental iron therapy and patients require repeated transfusions. Amongst patients with preexisting co-morbidities, repeated bleeding may lead to significant morbidity and mortality. Furthermore, re-bleeding among these patients consumes a disproportionate share of healthcare resources devoted to multiple admissions, repeated endoscopies and blood transfusions. There are no effective treatment options available currently. The purpose of this study is to determine whether Thalidomide is effective in the treatment of arteriovenous malformations in the gastrointestinal tract.
IMPORTANCE: There are still doubts about long-term satisfaction rates of native tissue uterine preserving surgical techniques for pelvic organ prolapse.
OBJECTIVE: The objective of this study was to compare long-term subjective success rates and satisfaction rates between vaginal sacrospinous hysteropexy (SSHP) and vaginal hysterectomy with uterosacral ligament suspension (VH-USLS).
STUDY DESIGN: This was a retrospective single-center, observational matched cohort study in women receiving either SSHP or VH-USLS between 2004 and 2021. Primary outcome was overall subjective success (combined outcome of absence of bulge nor retreatment, and satisfaction with operation) at least 12 months after surgery. Satisfaction with the operation was defined as a combined Patient Global Impression of Improvement rating ≤ 2 and a patient satisfaction score ≥7.
RESULTS: Of 583 patients, 192 patients could be matched (SSHP, 96; VH-USLS, 96), with 55% (SSHP, 60; VH-USLS, 45) participating at the telephone interview. Mean follow-up time was 77 months for VH-USLS, and 36 months for SSHP, respectively. No difference in overall subjective success rates was found between the groups (45% VH-USLS and 51% SSHP; P = 0.54). Overall satisfaction was similar between both groups (70% vs 71%, P = 0.90). Logistic regression found no influence of duration of follow-up and the overall subjective success rate. Both procedures would be recommended to a relative or friend by a large majority of patients (88% vs 85%, P = 0.761). Operative time and hospitalization time were significantly shorter in the SSHP group. No serious complications were reported.
CONCLUSIONS: Overall success rates did not differ between both procedures after at least 1 year of follow-up with relatively high satisfaction rates. Sacrospinous hysteropexy had shorter operative time and shorter duration of hospitalization.
Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about any benefits that have arisen because of the cancer diagnosis.